Other antibodies against C-type lectin domain family 12 member A (CLL-1) [77], mainly expressed in AML LSC specifically, CD47 [78], and IL-1 receptor accessory protein (IL1RAP), which stimulates oncogenic activity in AML through activation of the innate immune signaling pathway [79], have also been suggested as therapeutic candidates. The gene discussed is CD47; the disease is acute myeloid leukemia.